Market news
Neurocrine Biosciences (NBIX) has an average rating of buy and mean price target of $209.12, accordi
On August 12, Neurocrine Biosciences (NASDAQ:NBIX) published something unusual for a psychiatric drug: proof that patients feel the difference, not just that a clinician’s scale says they moved less. The KINECT-PRO findings showed INGREZZA easing the daily burden of tardive dyskinesia in ways a rating scale alone never captures. The timing matters, because the data […]
Neurocrine Biosciences' (NBIX) Ingrezza and Crenessity products are expected to drive H2 appreciatio
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Neurocrine Biosciences (NBIX) drew investor attention after the FDA accepted its Investigational New Drug application for a Phase 2 trial of NBI-1117567 in Alzheimer’s cognition, marking a fresh clinical milestone in its Nxera partnership. Despite the FDA news, Neurocrine Biosciences’ recent 30 day share price return is down 14.72%. However, the year to date share price return of 10.90% and 1 year total shareholder return of 12.22% point to momentum that has built over a longer horizon. Scan...
Nxera Pharma recently announced that its partner Neurocrine Biosciences received FDA IND acceptance for a Phase 2 trial of NBI-1117567, an investigational oral muscarinic M1-preferring agonist for Alzheimer’s cognition, triggering a US$10,000,000 milestone payment to Nxera in Third Quarter Fiscal Year 2026. This IND milestone advances Neurocrine’s broader muscarinic receptor collaboration with Nxera, underscoring its push into Alzheimer’s-related cognitive symptoms alongside existing...
Neurocrine Biosciences stock has delivered a solid 5 year return while recent trading has been more mixed, and the current share price around US$156 still raises the question of how much value is already reflected. With the broader valuation checks leaning supportive and the market multiples screening as roughly in line with peers, investors are weighing whether the stock still offers an attractive entry point. Over the past 5 years Neurocrine Biosciences has returned 63.8%, which puts the...
Neurocrine Biosciences (NasdaqGS: NBIX) reported that the FDA has accepted its Investigational New Drug application for NBI-1117567 targeting Alzheimer's related cognition. The acceptance clears the way for a Phase 2 clinical study of NBI-1117567 in patients with cognitive symptoms linked to Alzheimer's disease. This IND milestone adds another clinical stage asset to Neurocrine Biosciences' development pipeline in a high unmet need area. This kind of progress in Alzheimer's drug development...
NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with NeurocrineNxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone packageNxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan Tokyo, Japan and Cambridge, UK, 26 August 2026 – Nxera Pharma Co., Ltd.
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Neurocrine Biosciences (NBIX) buy thesis: Ingrezza-led cash flows, new launches, and pipeline optionality. Read here for a detailed analysis.
NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.
About This EventNeurocrine Biosciences (Nasdaq: NBIX), a leading biopharmaceutical company, visits the Nasdaq MarketSite in Times Square.In honor of the occasion, Kyle Gano, Chief Executive Officer of Neurocrine Biosciences, rings the Opening Bell.
Neurocrine Biosciences (NBIX) has an average rating of buy and mean price target of $210.27, accordi
Neurocrine Biosciences (NASDAQ:NBIX) shares dropped 5. 8% following reports of patient deaths and serious adverse events potentially associated with Vykat, a treatment for Prader-Willi syndrome.
Neurocrine Biosciences (NBIX) stock dips as safety concerns linked to the company's newly acquired rare disease drug, Vykat XR, resurface. Read more here.
In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, sharply higher than a year earlier and ahead of analyst expectations, with INGREZZA, CRENESSITY, and newly acquired VYKAT XR leading record sales. The company also raised its full-year INGREZZA sales guidance and reinforced its leadership bench with new senior appointments, underscoring an ambition to build a broader, multi-product neuroscience business backed by one...
Neurocrine Biosciences appointed a new Chief Business Officer and three Senior Vice Presidents to its senior leadership team. The moves come as the company advances its commercial portfolio and clinical pipeline. These leadership changes mark another step in Neurocrine Biosciences' evolution into a more diversified biopharmaceutical company. Neurocrine Biosciences, traded as NasdaqGS:NBIX, is drawing attention after this management reshuffle, which arrives alongside an active commercial...
Neurocrine Biosciences (NBIX) has an average rating of buy and mean price target of $198.44, accordi
Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The
Neurocrine Biosciences (NBIX) has an average rating of buy and mean price target of $209.63, accordi
Neurocrine Biosciences (NBIX) has an average rating of buy and mean price target of $209.63, accordi
Neurocrine Biosciences (NBIX) stock is in focus after the company reported second quarter 2026 revenue of US$959 million and net income of US$144.4 million, alongside updated full year guidance for INGREZZA. See our latest analysis for Neurocrine Biosciences. Despite strong Q2 results and higher INGREZZA guidance, Neurocrine Biosciences shares fell about 10% in the last trading day and are down around 5% over the past week. However, a 26% 3 month share price return and 29% 1 year total...
Moby summary of Neurocrine Biosciences, Inc.'s Q2 2026 earnings call
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Neurocrine Biosciences (NBIX) reported Q2 adjusted earnings late Thursday of $2.85 per diluted share
This is the newest page. Registered accounts read further back.